Biosimilars Versus Generics: Differences in the Regulatory Review Process

Name: Biosimilars Versus Generics: Differences in the Regulatory Review Process
Uploaded: 2018-12-04T06:43:00.000Z
Description: Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, discusses the regulatory review process for biosimilars and how it differs from the generic approval process.

December 4, 2018

Article

Conference|ASHP Midyear Clinical Meeting and Exhibition - American Society of Health System Pharmacists Midyear Clinical Meeting and Exhibition

Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, discusses the regulatory review process for biosimilars and how it differs from the generic approval process.

At the American Society for Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition, Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, discussed the regulatory review process for biosimilars and how it differs from the generic review process.